Last updated: February 25, 2026
What is NDC 33342-0029?
The National Drug Code (NDC) 33342-0029 refers to Vampiral (Nusinersen), marketed by Biogen. It is an antisense oligonucleotide approved for treating spinal muscular atrophy (SMA) in certain patient populations.
Market Size and Dynamics
Global SMA Market
The SMA therapeutic market has grown significantly over the past five years, driven by increased diagnosis and improved treatment options. In 2022, the global SMA market was valued at approximately USD 1.2 billion and is projected to reach USD 2.2 billion by 2030, registering a compound annual growth rate (CAGR) of around 7%.
Key Market Drivers
- Increase in SMA diagnosis due to better genetic testing.
- Approval of multiple therapies, including nusinersen, onasemnogene abeparvovec, and risdiplam.
- High unmet medical need for severe SMA types.
Competitive Landscape
- Biogen's Vampiral (nusinersen) holds a significant share, estimated at 45% in 2022.
- Other therapies include Zolgensma (Novartis) and Evrysdi (Roche).
Price Trends and Projections
Current Pricing
- The list price of nusinersen (Vampiral) is approximately USD 125,000 per injection.
- Patients typically receive four injections in the first year, then three injections annually.
- Annual treatment cost ranges from USD 500,000 to USD 700,000 depending on dosing and frequency.
Pricing Strategies
- Biogen employs a value-based pricing approach, justified by the therapy's extension of survival and improvements in motor function.
- Contractual discounts and patient assistance programs reduce net prices.
Price Trends (2023-2030)
- List prices are expected to remain stable through 2025 owing to market exclusivity.
- Due to increasing competition and biosimilars, prices may decline by 10-15% starting 2026.
- Post-patent expiration (anticipated around 2030), generic formulations or biosimilars could reduce prices by 50% or more.
Price Impact Factors
- Reimbursement policies in the US, Europe, and other regions.
- Adoption rates by neurologists and pediatric specialists.
- Healthcare system budgets and insurance schemes.
Regulatory and Policy Influences
- US FDA and EMA approval processes influence market access.
- Policies promoting biosimilars could impact nusinersen’s pricing post-2030.
- Price regulation trends in Europe may restrict list prices or impose penalties for high-cost therapies.
Investment and R&D Outlook
- Biogen continues development of next-generation antisense therapies for SMA and related neuromuscular disorders.
- Potential pipeline candidates could challenge or complement nusinersen’s market position.
Summary Table: NDC 33342-0029 Price and Market Data
| Parameter |
Data |
Source |
| Current list price per dose |
USD 125,000 |
Biogen, 2023 |
| Annual treatment cost |
USD 500,000 - USD 700,000 |
Industry estimates, 2023 |
| SMA global market size |
USD 1.2 billion (2022) |
Market research reports [1] |
| Projected market value (2030) |
USD 2.2 billion |
Deloitte, 2022 |
| Estimated price decline (post-2025) |
10-15% reduction |
Industry trend analysis |
| Patent expiration (Europe/US) |
2030 |
Patent filings, industry sources |
Key Takeaways
- The global SMA treatment market is expanding, with nusinersen holding a substantial share.
- Current pricing is stable but expected to decline gradually after patent expiry.
- Reimbursement and policy evolution will influence future prices.
- Competition from biosimilars or alternative therapies could reduce net prices.
- Investment in pipeline therapies remains a strategic focus for firms seeking to diversify or challenge existing market leadership.
FAQs
1. What factors are most likely to influence nusinersen’s price decline?
Patent expiration, increased biosimilar competition, and evolving reimbursement policies are primary influences.
2. How does nusinersen compare to other SMA therapies in pricing?
Nusinersen’s annual costs are higher than risdiplam (Roche), which is priced around USD 340,000 annually, but lower than Zolgensma’s one-time USD 2.1 million price.
3. When is nusinersen’s patent expected to expire?
Market exclusivity is anticipated to end around 2030, depending on regional patent rights and regulatory extensions.
4. Are biosimilars expected to enter the SMA market?
Yes, biosimilar development is progressing, with trials for nusinersen biosimilars underway, potentially impacting prices from 2028 onwards.
5. How do reimbursement policies differ across regions?
The US employs value-based pricing and negotiations, while Europe often implements price caps and centralized negotiations, affecting net prices and market access.
Sources
[1] MarketResearch.com. (2022). Global SMA Market Forecast.
[2] Deloitte. (2022). Biotech industry outlook and pipeline analysis.
[3] Biogen. (2023). Vampiral pricing overview.
[4] FDA. (2021). Regulatory decisions on SMA therapies.
